Initial receipt date: 11-MAY-2015
This information was received from a literature article concerning a patient of unknown age and gender who 
received Efavirenz and Zidovudine plus Lamivudine for HIV 1 infection. 
No relevant medical history, concurrent diseases and concomitant medications were reported.
In this open-label trial, HIV-1-infected patients with a CD4 plus cell count lower than 100 cells/ml were randomly 
assigned to receive an NNRTI-based antiretroviral regimen or a boosted PI-based regimen. Eligible patients were 
randomly assigned in a 1:1 ratio to receive zidovudine (ZDV, 300mg bid) plus lamivudine (3TC, 150mg bid) 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 431 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
(Combivir) with either efavirenz (Sustiva 600mg qd) as the NNRTI or indinavir-ritonavir (Crixivan/Norvir 800/100mg 
bid) as the ritonavir-boosted protease inhibitor-based regimen.
This patient was randomized to Zidovudine plus Lamivudine (Combivir) and efavirenz group.
On an unknown date, patient developed progressive multifocal leukoencephalopathy.
Action taken with suspect drugs and outcome of the event was unknown. 
Company physician considered the event serious due to important medical event.